The Expected Rise and Inevitable Fall of MannKind
BY Adam Feuerstein | 06/05/14
the stock has more room to run into the Afrezza July 15 approval decision date.
NDA & MAA filings excepted by end of 2014 on ICPT
Mannkind Afrezza FDA Panel Epilogue Plus a Mea Culpa
BY Adam Feuerstein | 04/02/14 - 06:07 AM EDT
NEW YORK (TheStreet) -- Mannkind (MNKD_) By a 13-1 margin, experts on the panel voted to recommend the approval of Afrezza as a new insulin therapy for Type 1 diabetics. The same panel supported Afrezza use in Type 2 diabetics by a 14-0 vote.
Congratulations to Mannkind and its supporters, who were clearly right to believe in Afrezza's approval chances. The panel votes were overwhelmingly positive and should compel the FDA to approve the new in
haled insulin. Mannkind skeptics who believed FDA criticism of Afrezza would persuade the panel to reject the new insulin were wrong. I was one of those Afrezza non-believers, predicting a negative panel vote for both Type 1 and Type 2 diabetes. I was wrong.